R&D pipeline

1.Development stage and area

Region Exploratory Clinical Study
Phase 2
Confirmatory Clinical Study
Phase 3
NDA filed
Japan

Y-39983
<Glaucoma>

Difluprednate
<DME>

   
OVERSEAS  

Bromfenac
<Inflammation>
Russia

Gatifloxacin
<Infection>
China

Bromfenac
<Infection>
Vietnam

Hyaluronate
<CCED*>
Vietnam

* CCED: Corneal and Conjunctival epithelial disorders

2.Product information

DrugCode nameDosage FormMechanisum of actionIndication
Y-39983SNJ-1656Topical ophthalmic solutionRho kinase inhibitorGlaucoma
Difluprednate SJE-2079 Topical ophthalmic emulsion Corticosteroid Diabetic macular edema (DME)
Gatifloxacin   Topical ophthalmic suspension Antibiotics Ocular infections
Bromfenac   Topical ophthalmic suspension NSAID Ocular inflammations
Sodium hyaluronate   Topical ophthalmic suspension Protection of surface epithelium Corneal and Conjunctival epithelial disorders

3.Additional information

Y-39983Y-39983 has a mechanism of action by increasing outflow of aqueous humor through the trabecular mechwork.
Difluprednate Difluprednate eye drop is a corticosteroid which has strong anti-inflammatory effect.
Penetration of the drug into the eye is increased by unique emulsification technology.
Gatifloxacin There is less resistance with fourth generation quinolones beause these drugs bind to both DNA gyrase and topoisomerase IV in bacterial chromosome and cause lethal breaks.
Brand name in china will be 格替.
Bromfenac Brand name in Vietnam will be BRONUCK.
Brand name in Russia will be NUCKONE.
Sodium hyaluronate Brand name in Vietnam will be TEARBALANCE.